



**PRESS RELEASE**

08 July 2025 13:00:00 CEST

## **Invitation to presentation of Senzime's second quarter 2025 report**

**Senzime AB (publ.) invites investors, analysts, and media to a webcast presentation of the second quarter report for 2025 on July 18, 13:00 CEST. The report will be published during the morning of the same day.**

The presentation will be held by Philip Siberg, CEO of Senzime, and after the presentation, there will be a Q&A session moderated by Klas Palin, analyst at Carnegie Investment Bank. The presentation will be held in English.

Date and time: Friday, July 18, 13:00 CEST

The presentation will be accessible at Senzime's website <https://www.senzime.com/investors>

Questions to moderator can be emailed in advance, no later than 10:00 am CEST on July 18 on: [klas.palin@carnegie.se](mailto:klas.palin@carnegie.se)

**For further information, please contact:**

---

Philip Siberg, CEO of Senzime AB

Phone: +46 (0) 707 90 67 34, e-mail: [philip.siberg@senzime.com](mailto:philip.siberg@senzime.com)

Slavoljub Grujicic, CFO

Phone: +46 (0) 76 306 60 11, e-mail: [slavoljub.grujicic@senzime.com](mailto:slavoljub.grujicic@senzime.com)

### **About Senzime**

---

Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at [senzime.com](https://www.senzime.com).

## Attachments

---

Invitation to presentation of Senzime's second quarter 2025 report